GLP-1 access in California: telehealth rules, licence lookups and Medicaid coverage

The card above is California's record from our state data file, and the sections below say what each line means and where it comes from. Rules on this page were checked on September 4, 2026; the linked sources are the authority if anything has moved since.

Who licenses prescribers in California

Physicians who treat patients located in California are licensed by the Medical Board of California (DCA licence search). The board's lookup is at search.dca.ca.gov/, which loaded when we checked on September 4, 2026. One search covers every California Department of Consumer Affairs board, including the Osteopathic Medical Board and the Board of Pharmacy. Nurse practitioners are licensed by the state nursing board and physician assistants by the medical board or their own board, depending on the state; the prescriber licence explainer walks through each search and what an active record does and does not tell you. Cross-check the name against the federal NPI Registry, which lists every US prescriber with credential and practice location.

The pharmacy that fills the prescription is licensed by the California State Board of Pharmacy. That includes pharmacies in other states that ship to a California address; they hold a non-resident licence from the same board. The Compounding Explained site covers what to search for once you are on the board site.

Telehealth prescribing in California

California does not require an in-person examination before a prescriber issues a prescription for a non-controlled drug after a telehealth visit. Prescribing requires an appropriate prior examination and medical indication, but the statute states that examination can be achieved through telehealth, including a self-screening tool or questionnaire, so no in-person or even synchronous encounter is required. The text we read is Cal. Bus. & Prof. Code § 2242, on September 4, 2026. The prescriber still has to meet the same standard of care as in an office, which for a GLP-1 means a real history, a weight and medication review, and a plan for follow-up.

California is not a member of the Interstate Medical Licensure Compact, so an out-of-state physician needs a California licence obtained the ordinary way or another authorisation the board recognises. Not a member. A physician needs a California licence to treat a patient located in California. None of this covers controlled substances, which add a federal layer; GLP-1s are not controlled. The cross-state telehealth explainer has the general pattern.

Medicaid and anti-obesity drugs in California

As of January 1, 2026, California Medicaid fee-for-service did not cover GLP-1s prescribed for obesity (Wegovy, Zepbound, Saxenda for weight management). Source: DHCS Medi-Cal Rx provider notice: changes effective January 2026. Medi-Cal Rx removed Wegovy, Zepbound and Saxenda for weight-loss indications effective January 1, 2026 under the 2025-26 state budget. Members under 21 can still be reviewed under EPSDT, and non-obesity indications are unaffected. Coverage of the same molecules for type 2 diabetes (Ozempic, Mounjaro) is a separate question and is usual. Federal law lets states exclude "agents used for weight loss" from Medicaid drug coverage (42 U.S.C. 1396r-8(d)(2)), which is why coverage varies state by state and can change with a budget. Managed-care plans in California may follow the state list or their own; the preferred drug list explainer shows where to look.

Compounded GLP-1s in California

We have not found a California-specific statute, rule or board notice on compounded GLP-1s that we could verify, so this page does not state one. The California State Board of Pharmacy is the regulator for a 503A pharmacy in the state and for non-resident pharmacies shipping into it; its newsletters and board minutes are where a state position would appear. The federal baseline applies everywhere: FDA declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage resolved on February 21, 2025, and after the enforcement-discretion periods it announced (503A pharmacies through February 18, 2025 for tirzepatide and April 22, 2025 for semaglutide) pharmacies may not compound what is essentially a copy of an approved product outside the narrow exceptions in federal law (FDA statement). On March 3, 2026 FDA sent warning letters to 30 telehealth companies over the marketing of compounded GLP-1s (FDA press release). Compounded semaglutide and tirzepatide are not FDA approved and are not interchangeable with Wegovy, Zepbound, Ozempic or Mounjaro.

Before you buy from a telehealth offer in California

1. Ask for the prescriber's full name and look it up on the Medical Board of California (DCA licence search) lookup above. An active licence in California is the minimum, not an endorsement.
2. Ask which pharmacy will fill the prescription and check it on the California State Board of Pharmacy site, including a non-resident licence if the pharmacy is elsewhere.
3. If the product is compounded, expect it to be described as compounded and not FDA approved, and ask for the certificate of analysis. The Compounding Explained site has a vetting checklist; the FormBlends regulatory status page tracks the federal position.
4. Price the offer against brand self-pay programs and other compounded programs using the GLP-1 Pricing Index and the FormBlends cost report, and use the clinic fit quiz to decide which care model suits you. If you are new to tirzepatide, the FormBlends tirzepatide introduction covers the drug itself, and the FormBlends directory lists licensed providers and pharmacies.